GTCR announced it has completed the acquisition of Zentiva, a European generics pharmaceutical company, from Advent, marking a new phase of growth for the business.
Zentiva focuses on developing, manufacturing, and supplying generic, branded specialty, and over the counter medicines to more than 100 million people across over 40 countries. The company operates with established research and development capabilities and a broad portfolio aimed at delivering high quality, affordable medicines.
GTCR will partner with Zentiva’s leadership team, including Chief Executive Officer Steffen Saltofte and Executive Chairperson Kieran Murphy, to support expansion through investment in product development, portfolio diversification, and geographic reach. The firm emphasized its long history of healthcare investing and its intention to strengthen access to essential medicines while supporting sustainable healthcare systems.
The transaction positions Zentiva to build on its existing scale, manufacturing capabilities, and market presence across Europe.
KEY QUOTES:
“We are proud of Zentiva’s strong history and footprint. We look forward to partnering with GTCR at an important inflection point following several years of growth. With GTCR’s support and significant industry expertise, we believe we are ideally placed to accelerate our momentum and continue our mission of expanding access to high-quality, affordable medicines to millions of people across Europe.”
Steffen Saltofte, Chief Executive Officer of Zentiva
“We are excited to partner with Steffen and the Zentiva team to further the Company’s success. As policymakers increasingly prioritize expanding access to essential medicines while ensuring long-term sustainability of healthcare systems, Zentiva plays a critical role in delivering high-quality, cost-effective therapies at scale. Combined with its differentiated geographic footprint and low-cost manufacturing capabilities, Zentiva is well positioned to strengthen its competitive advantage and deliver long-term growth and impact.”
Sean Cunningham, Managing Director and Head of Healthcare at GTCR
“We are immensely proud of the business Zentiva has become during our partnership, a scaled, growing European generics platform, with a strong competitive footprint, a commitment to quality, and a clear mission to expand access to affordable medicines. We would like to thank Steffen and all the talented Zentiva team members who played a part in the company’s transformation. We look forward to watching Zentiva go from strength to strength in the years ahead.”
Tom Allen, Managing Director at Advent
